Literature DB >> 31102164

Recovery-Oriented Outcomes Associated with Long-Acting Injectable Antipsychotics in an Urban Safety-Net Population.

Kei Yoshimatsu1, Andrea Elser2, Melanie Thomas2, James Dilley2, Deborah Barnes2, Alexandra Ballinger2, Steven Wozniak3, Christina Mangurian2.   

Abstract

This study examined whether transitioning patients from oral antipsychotics (POs) to long-acting injectable antipsychotics (LAIs) helps patients achieve recovery-oriented goals. Data was extracted from San Francisco County's electronic medical record system for this retrospective pre-post observational study. Patients reflect a safety-net population treated in community-based mental health settings during 2015. The San Francisco Adult Strengths and Needs Assessment (SF ANSA), a measure of psychosocial functioning, was used to assess within-subject change when treated with POs versus LAIs. In our study sample (N = 77), LAI SF ANSA scores showed significant improvements in criminal behaviors (p = .017), medication adherence (p = .008), and spirituality (p = .028), and a non-significant trend for residential stability (p = .073). This is the first study to evaluate improvements in key psychosocial areas after treatment with LAIs. This work suggests that LAIs can be another tool for providers to help patients work towards their recovery-oriented goals.

Entities:  

Keywords:  Depot medications; Long-acting injectable antipsychotic medications; Psychosis; Recovery; Schizophrenia

Year:  2019        PMID: 31102164     DOI: 10.1007/s10597-019-00412-w

Source DB:  PubMed          Journal:  Community Ment Health J        ISSN: 0010-3853


  11 in total

1.  Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response.

Authors:  Jean-Pierre Lindenmayer; Hong Liu-Seifert; Pandurang M Kulkarni; Bruce J Kinon; Virginia Stauffer; Sara E Edwards; Lei Chen; David H Adams; Haya Ascher-Svanum; Peter F Buckley; Leslie Citrome; Jan Volavka
Journal:  J Clin Psychiatry       Date:  2009-06-02       Impact factor: 4.384

2.  How Occupationally High-Achieving Individuals With a Diagnosis of Schizophrenia Manage Their Symptoms.

Authors:  Amy N Cohen; Alison B Hamilton; Elyn R Saks; Dawn L Glover; Shirley M Glynn; John S Brekke; Stephen R Marder
Journal:  Psychiatr Serv       Date:  2016-11-15       Impact factor: 3.084

3.  Long-acting risperidone and oral antipsychotics in unstable schizophrenia.

Authors:  Robert A Rosenheck; John H Krystal; Robert Lew; Paul G Barnett; Louis Fiore; Danielle Valley; Soe Soe Thwin; Julia E Vertrees; Matthew H Liang
Journal:  N Engl J Med       Date:  2011-03-03       Impact factor: 91.245

4.  A 6-Month Prospective Trial of a Personalized Behavioral Intervention + Long-Acting Injectable Antipsychotic in Individuals With Schizophrenia at Risk of Treatment Nonadherence and Homelessness.

Authors:  Martha Sajatovic; Luis F Ramirez; Edna Fuentes-Casiano; Jamie Cage; Curtis Tatsuoka; Michelle E Aebi; Ashley Bukach; Kristin A Cassidy; Jennifer B Levin
Journal:  J Clin Psychopharmacol       Date:  2017-12       Impact factor: 3.153

5.  Comparison of long-acting and oral antipsychotic treatment effects in patients with schizophrenia, comorbid substance abuse, and a history of recent incarceration: An exploratory analysis of the PRIDE study.

Authors:  H Lynn Starr; Jason Bermak; Lian Mao; Steve Rodriguez; Larry Alphs
Journal:  Schizophr Res       Date:  2017-06-07       Impact factor: 4.939

6.  Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge.

Authors:  Steven C Marcus; Jacqueline Zummo; Amy R Pettit; Jeffrey Stoddard; Jalpa A Doshi
Journal:  J Manag Care Spec Pharm       Date:  2015-09

7.  Adherence to antipsychotic medication among homeless adults in Vancouver, Canada: a 15-year retrospective cohort study.

Authors:  Stefanie N Rezansoff; A Moniruzzaman; S Fazel; R Procyshyn; J M Somers
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2016-06-23       Impact factor: 4.328

Review 8.  Assessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry.

Authors:  John M Kane; Taishiro Kishimoto; Christoph U Correll
Journal:  J Clin Epidemiol       Date:  2013-08       Impact factor: 6.437

Review 9.  The Use of Long-Acting Injectable Antipsychotics in Schizophrenia.

Authors:  Seiya Miyamoto; W Wolfgang Fleischhacker
Journal:  Curr Treat Options Psychiatry       Date:  2017-04-19

Review 10.  Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia.

Authors:  Gabriel Kaplan; Julio Casoy; Jacqueline Zummo
Journal:  Patient Prefer Adherence       Date:  2013-11-13       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.